All In Biotech

Drug Trial Radar · NCT03331198

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Nov 27, 2017

Primary completion

Nov 26, 2027

Study completion Nov 26, 2027

Sponsor

Lead sponsor
Juno Therapeutics, a Subsidiary of CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Small Lymphocytic

Interventions

  • JCAR017 (lisocabtagene maraleucel)Biological

    Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

  • JCAR017 (lisocabtagene maraleucel) + ibrutinibBiological

    Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

  • JCAR017 (lisocabtagene maraleucel) + venetoclaxBiological

    Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 JCAR017 monotherapy arm: adverse eventsTime frame: Up to 48 months post treatment
  2. Phase 1 JCAR017 monotherapy arm: laboratory abnormalitiesTime frame: Up to 48 months post treatment
  3. Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: adverse eventsTime frame: Up to 48 months post treatment
  4. Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: laboratory abnormalitiesTime frame: Up to 48 months post treatment
  5. Phase 1 JCAR017 and ibrutinib combination dose expansion therapy armTime frame: Through post treatment up to Month 48
  6. Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: adverse eventsTime frame: Up to 48 months post treatment
  7. Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: laboratory abnormalitiesTime frame: Up to 48 months post treatment
  8. Phase 1 JCAR017 and venetoclax combination dose expansion therapy armTime frame: Through post treatment up to Month 48
  9. Phase 2 JCAR017 monotherapy expansion armTime frame: Through post treatment up to Month 48
  10. Phase 2 JCAR017 Double exposed monotherapy expansion arm: overall response rate (ORR)Time frame: Up to approximately 24 months

Locations

84 sites in 2 countries. Site status is shown where the registry gives one.

  • Local Institution - 0006

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Local Institution - 0043

    Gilbert, Arizona

  • City of Hope

    Duarte, California

  • Local Institution - 0007

    Duarte, California

  • Local Institution - 0025

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Local Institution - 0059

    Los Angeles, California

  • University of California, Los Angeles

    Los Angeles, California

  • Local Institution - 0010

    San Francisco, California

  • University of California, San Francisco

    San Francisco, California

  • Local Institution - 0111

    Denver, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Local Institution - 0085

    Washington D.C., District of Columbia

  • Local Institution - 0080

    Jacksonville, Florida

  • Mayo Clinic

    Jacksonville, Florida

  • Local Institution - 0104

    Atlanta, Georgia

  • Local Institution - 0019

    Atlanta, Georgia

  • The Blood and Marrow Transplant Group of Georgia (BMTGA)

    Atlanta, Georgia

  • Local Institution - 0003

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • Local Institution - 0016

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • Local Institution - 0105

    Indianapolis, Indiana

  • Local Institution - 0107

    Wichita, Kansas

  • Local Institution - 0064

    Louisville, Kentucky

  • Local Institution - 0027

    New Orleans, Louisiana

  • Local Institution - 0005

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Local Institution - 0015

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Local Institution - 0084

    Ann Arbor, Michigan

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Local Institution - 0062

    Detroit, Michigan

  • Local Institution - 0109

    Detroit, Michigan

  • Local Institution - 0054

    Rochester, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Local Institution - 0008

    Omaha, Nebraska

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.